The estimated Net Worth of Mark Louis Friedman is at least 355 千$ dollars as of 16 March 2022. Mark Friedman owns over 6,000 units of Axogen stock worth over 343,222$ and over the last 13 years he sold AXGN stock worth over 11,675$. In addition, he makes 0$ as Vice President - Regulatory Affairs and Quality Assurance at Axogen.
Mark has made over 8 trades of the Axogen stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of AXGN stock worth 79,680$ on 16 March 2022.
The largest trade he's ever made was exercising 67,767 units of Axogen stock on 24 October 2017 worth over 174,839$. On average, Mark trades about 3,164 units every 138 days since 2011. As of 16 March 2022 he still owns at least 25,845 units of Axogen stock.
You can see the complete history of Mark Friedman stock trades at the bottom of the page.
Dr. Mark Louis Friedman Ph.D. serves as Vice President - Regulatory Affairs and Quality Assurance of the Company. Dr. Friedman has served as Axogen’s Vice President of Regulatory Affairs and Quality Assurance since November 2011. He has also served as Axogen’s Director of Quality Assurance and Regulatory Affairs from September 2006 to June 2011. Prior to joining Axogen, Dr. Friedman held several regulatory and quality leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance from 1997 to 1998 and Vice President of Quality and Regulatory from 1998 to 2001 and from 2004 to 2005. Dr. Friedman also worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory from 2001 to 2004 and as Vice President of Operations in 2004. AtriCure acquired Enable Medical in 2005. Dr. Friedman has over 25 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with start-up medical product firms. Dr. Friedman has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati. Dr. Friedman sits on various agency committees for the Alliance of Regenerative Medicine, Medical Device Manufacturer’s Association and American Association of Tissue Banks, working on improving regulatory laws and standards for regenerative products and medical devices.
Mark Friedman is 62, he's been the Vice President - Regulatory Affairs and Quality Assurance of Axogen since 2011. There are 4 older and 11 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
Mark's mailing address filed with the SEC is 13631 PROGRESS BOULEVARD, SUITE 400, ALACHUA, FL, 32615.
Over the last 14 years, insiders at Axogen have traded over 73,805,978$ worth of Axogen stock and bought 504,297 units worth 3,119,117$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Guido J Neels、Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of 455,132$. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth 158,085$.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: